Anti-CD25 [7D4]
Catalogue Number: AB02216-203.0-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | IL-2-RA; Interleukin-2 receptor subunit alpha; IL-2 receptor subunit alpha; IL-2R subunit alpha; IL2-RA; p55 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 50 ug |
| Host name: | Rat |
| Clone: | 7D4 |
| Isotype: | IgM |
| Immunogen: | The original rat IgM version of this antibody was raised by immunizing Lewis rats with HT2 cells in complete Freund's adjuvant via a intraperitoneal injection and subsequent generation of hybridomas. |
| Application: | FC, Depl |
Additional Text
Gene Name
IL2RA
Gene ID
16184
Uniprot ID
P01590
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Application Notes
7D4 is a non-IL-2 blocking anti-CD25 antibody that has been widely used to identify CD25-positive cells via flow cytometry (Kohyama et al., 2012; pmid: 22399592), for instance, to analyse Lymph node cells from BALB/c mice that were untreated or treated with 0.25 mg PC61 (Onizuka et al., 1999; pmid: 10397255) or to characterize brain-infiltrating immune cells (Maes et al., 2013). Although 7D4 does not inhibit IL-2 binding itself, it shows synergistic qualities with a cancer vaccine; namely, 7D4 with a cancer vaccine boosted the vaccine-induced anti-tumour response. Furthermore, this antibody was shown to be able to induce inactivation of regulatory T cells (Treg); the effect was particularly significant when this clone was used synergistically with another anti-CD25 clone - PC61 (Ab01107) (Kohm et al., 2006; pmid: 16517695; McNeill et al., 2007; pmid: 17212768). 7D4, when turned into a mouse IgG2a format, exhibits depleting qualities against Treg cells and can be used to remove Treg lymphocytes from the tumoral environment without blocking CD25 (IL-2 pathway) on T effector cells (Solomon et al., 2020). As a result, it can be utilized as a potential immunotherapy agent achieving Treg depletion without T effector cells' debilitation (Solomon et al., 2020). Finally, it was demonstrated that such anti-CD25 non-IL-2 blocking antibodies are successful agents in promoting effector activation and leading to strong antitumor activity (Solomon et al., 2020).
AB02216-203.0 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations